PRS:当前对乳房植入物的安全性和实用性的看法

2021-03-14 MedSci原创 MedSci原创

改进的方框标签可以提高非专业女性对乳房植入物安全性及效用的看法,并影响决策。然而,对乳房植入物的更严格的审查不应该阻止需要隆胸的女性接受隆胸。 鉴于乳房植入物在乳房重建和隆胸中发挥着重要作用,医生们应

关于乳房植入物与间变性大细胞淋巴瘤(BIAALCL)相关的证据越来越多,使得乳房假体的安全性成为一个突出的问题。仅在美国就有300多例BIA-ALCL病例被记录在案,无数其他妇女报告了与乳房假体相关的全身症状,统称为乳房假体疾病。

尽管如此,假体乳房手术仍是整形外科医生最常进行的手术之一。因此,美国食品和药物管理局(FDA)已经采取措施。通过普通和整形外科设备咨询小组以及随后召回Allergan Biocell假体。在美国食品和药物管理局(FDA)介入后,公众对乳房植入物安全性的担忧与日俱增。事实上,美国食品和药物管理局(U.S.Food and Drug Administration,简称FDA)最近建议对隆胸标签进行修改,其中包括方框警告。

鉴于提高乳房植入物安全透明度的努力,该研究评估了非专业女性对乳房植入物安全性的看法,以及乳房植入物标签拟议的改变对非专业女性乳房植入物决策的影响。

这是一项针对通过Amazon Mechanical Turk. 论坛所招募女性的横断面调查。离散选择建模用于在查看建议的标签更改后,查询受试者对乳房植入物的意见。亚组分析使用卡方和方差分析,McNemar分析用于评估参与者反应的变化。

作者共收到500份调查问卷。在基线时,353名参与者(70.6%)认为隆胸至少在一定程度上是安全的。在基线时,353名参与者(70.6%)认为乳房植入物至少在一定程度上是安全的。此外,参与者对乳房植入物作为医疗设备的看法因其个人植入物历史而有显著差异(p<0.001)。

在看到拟议的方框警告后,252名参与者(50.4%)回应说,他们接受植入物的可能性较小。

事实上,在观看了对植入物标签的建议更改后,认为隆胸不安全或非常不安全的参与者比例明显高于基线(58.4%对28.8%;p=0.001)。在调查结束时,考虑隆胸/再造的替代方案的意愿比基线显著增加。

改进的方框标签可以提高非专业女性对乳房植入物安全性及效用的看法,并影响决策。然而,对隆胸的更严格的审查不应该阻止需要隆胸的女性接受隆胸。

鉴于乳房植入物在乳房重建和隆胸中发挥着重要作用,医生们应该确保未来的对话继续围绕乳房植入物最显著的风险和好处展开。外科医生和患者对话的透明度和客观性可以确保适当使用乳房植入物等医疗设备

原始文献:

Yesantharao Pooja S,Lee Erica,Khavanin Nima et al. Thinking Outside the Black Box: Current Perceptions on Breast Implant Safety and Utility.[J] .Plast Reconstr Surg, 2021, 147: 593-603.

DOI: 10.1097/PRS.0000000000007626

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1669045, encodeId=e7341669045b9, content=<a href='/topic/show?id=bc2114e79b8' target=_blank style='color:#2F92EE;'>#PRS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14779, encryptionId=bc2114e79b8, topicName=PRS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=209526497271, createdName=kzlchina, createdTime=Thu Oct 14 15:31:36 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797709, encodeId=62171e9770951, content=<a href='/topic/show?id=8d1423633a6' target=_blank style='color:#2F92EE;'>#乳房植入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23633, encryptionId=8d1423633a6, topicName=乳房植入)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Sun Nov 21 16:31:36 CST 2021, time=2021-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2069707, encodeId=46732069e076c, content=<a href='/topic/show?id=ebbc4606222' target=_blank style='color:#2F92EE;'>#实用性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46062, encryptionId=ebbc4606222, topicName=实用性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Mon Nov 08 17:31:36 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948676, encodeId=02039486e69f, content=适度医疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0705459229, createdName=梅斯-Chengwen, createdTime=Tue Mar 16 13:46:46 CST 2021, time=2021-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490943, encodeId=feb01490943bc, content=<a href='/topic/show?id=fb916268636' target=_blank style='color:#2F92EE;'>#植入物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62686, encryptionId=fb916268636, topicName=植入物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38628846382, createdName=linagood, createdTime=Tue Mar 16 14:31:36 CST 2021, time=2021-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1520733, encodeId=14e91520e33b3, content=<a href='/topic/show?id=7a736264553' target=_blank style='color:#2F92EE;'>#植入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62645, encryptionId=7a736264553, topicName=植入)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=832411313664, createdName=jiyangfei, createdTime=Tue Mar 16 14:31:36 CST 2021, time=2021-03-16, status=1, ipAttribution=)]
    2021-10-14 kzlchina
  2. [GetPortalCommentsPageByObjectIdResponse(id=1669045, encodeId=e7341669045b9, content=<a href='/topic/show?id=bc2114e79b8' target=_blank style='color:#2F92EE;'>#PRS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14779, encryptionId=bc2114e79b8, topicName=PRS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=209526497271, createdName=kzlchina, createdTime=Thu Oct 14 15:31:36 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797709, encodeId=62171e9770951, content=<a href='/topic/show?id=8d1423633a6' target=_blank style='color:#2F92EE;'>#乳房植入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23633, encryptionId=8d1423633a6, topicName=乳房植入)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Sun Nov 21 16:31:36 CST 2021, time=2021-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2069707, encodeId=46732069e076c, content=<a href='/topic/show?id=ebbc4606222' target=_blank style='color:#2F92EE;'>#实用性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46062, encryptionId=ebbc4606222, topicName=实用性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Mon Nov 08 17:31:36 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948676, encodeId=02039486e69f, content=适度医疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0705459229, createdName=梅斯-Chengwen, createdTime=Tue Mar 16 13:46:46 CST 2021, time=2021-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490943, encodeId=feb01490943bc, content=<a href='/topic/show?id=fb916268636' target=_blank style='color:#2F92EE;'>#植入物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62686, encryptionId=fb916268636, topicName=植入物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38628846382, createdName=linagood, createdTime=Tue Mar 16 14:31:36 CST 2021, time=2021-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1520733, encodeId=14e91520e33b3, content=<a href='/topic/show?id=7a736264553' target=_blank style='color:#2F92EE;'>#植入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62645, encryptionId=7a736264553, topicName=植入)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=832411313664, createdName=jiyangfei, createdTime=Tue Mar 16 14:31:36 CST 2021, time=2021-03-16, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1669045, encodeId=e7341669045b9, content=<a href='/topic/show?id=bc2114e79b8' target=_blank style='color:#2F92EE;'>#PRS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14779, encryptionId=bc2114e79b8, topicName=PRS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=209526497271, createdName=kzlchina, createdTime=Thu Oct 14 15:31:36 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797709, encodeId=62171e9770951, content=<a href='/topic/show?id=8d1423633a6' target=_blank style='color:#2F92EE;'>#乳房植入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23633, encryptionId=8d1423633a6, topicName=乳房植入)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Sun Nov 21 16:31:36 CST 2021, time=2021-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2069707, encodeId=46732069e076c, content=<a href='/topic/show?id=ebbc4606222' target=_blank style='color:#2F92EE;'>#实用性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46062, encryptionId=ebbc4606222, topicName=实用性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Mon Nov 08 17:31:36 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948676, encodeId=02039486e69f, content=适度医疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0705459229, createdName=梅斯-Chengwen, createdTime=Tue Mar 16 13:46:46 CST 2021, time=2021-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490943, encodeId=feb01490943bc, content=<a href='/topic/show?id=fb916268636' target=_blank style='color:#2F92EE;'>#植入物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62686, encryptionId=fb916268636, topicName=植入物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38628846382, createdName=linagood, createdTime=Tue Mar 16 14:31:36 CST 2021, time=2021-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1520733, encodeId=14e91520e33b3, content=<a href='/topic/show?id=7a736264553' target=_blank style='color:#2F92EE;'>#植入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62645, encryptionId=7a736264553, topicName=植入)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=832411313664, createdName=jiyangfei, createdTime=Tue Mar 16 14:31:36 CST 2021, time=2021-03-16, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1669045, encodeId=e7341669045b9, content=<a href='/topic/show?id=bc2114e79b8' target=_blank style='color:#2F92EE;'>#PRS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14779, encryptionId=bc2114e79b8, topicName=PRS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=209526497271, createdName=kzlchina, createdTime=Thu Oct 14 15:31:36 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797709, encodeId=62171e9770951, content=<a href='/topic/show?id=8d1423633a6' target=_blank style='color:#2F92EE;'>#乳房植入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23633, encryptionId=8d1423633a6, topicName=乳房植入)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Sun Nov 21 16:31:36 CST 2021, time=2021-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2069707, encodeId=46732069e076c, content=<a href='/topic/show?id=ebbc4606222' target=_blank style='color:#2F92EE;'>#实用性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46062, encryptionId=ebbc4606222, topicName=实用性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Mon Nov 08 17:31:36 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948676, encodeId=02039486e69f, content=适度医疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0705459229, createdName=梅斯-Chengwen, createdTime=Tue Mar 16 13:46:46 CST 2021, time=2021-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490943, encodeId=feb01490943bc, content=<a href='/topic/show?id=fb916268636' target=_blank style='color:#2F92EE;'>#植入物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62686, encryptionId=fb916268636, topicName=植入物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38628846382, createdName=linagood, createdTime=Tue Mar 16 14:31:36 CST 2021, time=2021-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1520733, encodeId=14e91520e33b3, content=<a href='/topic/show?id=7a736264553' target=_blank style='color:#2F92EE;'>#植入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62645, encryptionId=7a736264553, topicName=植入)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=832411313664, createdName=jiyangfei, createdTime=Tue Mar 16 14:31:36 CST 2021, time=2021-03-16, status=1, ipAttribution=)]
    2021-03-16 梅斯-Chengwen

    适度医疗

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1669045, encodeId=e7341669045b9, content=<a href='/topic/show?id=bc2114e79b8' target=_blank style='color:#2F92EE;'>#PRS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14779, encryptionId=bc2114e79b8, topicName=PRS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=209526497271, createdName=kzlchina, createdTime=Thu Oct 14 15:31:36 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797709, encodeId=62171e9770951, content=<a href='/topic/show?id=8d1423633a6' target=_blank style='color:#2F92EE;'>#乳房植入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23633, encryptionId=8d1423633a6, topicName=乳房植入)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Sun Nov 21 16:31:36 CST 2021, time=2021-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2069707, encodeId=46732069e076c, content=<a href='/topic/show?id=ebbc4606222' target=_blank style='color:#2F92EE;'>#实用性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46062, encryptionId=ebbc4606222, topicName=实用性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Mon Nov 08 17:31:36 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948676, encodeId=02039486e69f, content=适度医疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0705459229, createdName=梅斯-Chengwen, createdTime=Tue Mar 16 13:46:46 CST 2021, time=2021-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490943, encodeId=feb01490943bc, content=<a href='/topic/show?id=fb916268636' target=_blank style='color:#2F92EE;'>#植入物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62686, encryptionId=fb916268636, topicName=植入物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38628846382, createdName=linagood, createdTime=Tue Mar 16 14:31:36 CST 2021, time=2021-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1520733, encodeId=14e91520e33b3, content=<a href='/topic/show?id=7a736264553' target=_blank style='color:#2F92EE;'>#植入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62645, encryptionId=7a736264553, topicName=植入)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=832411313664, createdName=jiyangfei, createdTime=Tue Mar 16 14:31:36 CST 2021, time=2021-03-16, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1669045, encodeId=e7341669045b9, content=<a href='/topic/show?id=bc2114e79b8' target=_blank style='color:#2F92EE;'>#PRS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14779, encryptionId=bc2114e79b8, topicName=PRS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=209526497271, createdName=kzlchina, createdTime=Thu Oct 14 15:31:36 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797709, encodeId=62171e9770951, content=<a href='/topic/show?id=8d1423633a6' target=_blank style='color:#2F92EE;'>#乳房植入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23633, encryptionId=8d1423633a6, topicName=乳房植入)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Sun Nov 21 16:31:36 CST 2021, time=2021-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2069707, encodeId=46732069e076c, content=<a href='/topic/show?id=ebbc4606222' target=_blank style='color:#2F92EE;'>#实用性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46062, encryptionId=ebbc4606222, topicName=实用性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Mon Nov 08 17:31:36 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948676, encodeId=02039486e69f, content=适度医疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0705459229, createdName=梅斯-Chengwen, createdTime=Tue Mar 16 13:46:46 CST 2021, time=2021-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490943, encodeId=feb01490943bc, content=<a href='/topic/show?id=fb916268636' target=_blank style='color:#2F92EE;'>#植入物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62686, encryptionId=fb916268636, topicName=植入物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38628846382, createdName=linagood, createdTime=Tue Mar 16 14:31:36 CST 2021, time=2021-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1520733, encodeId=14e91520e33b3, content=<a href='/topic/show?id=7a736264553' target=_blank style='color:#2F92EE;'>#植入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62645, encryptionId=7a736264553, topicName=植入)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=832411313664, createdName=jiyangfei, createdTime=Tue Mar 16 14:31:36 CST 2021, time=2021-03-16, status=1, ipAttribution=)]
    2021-03-16 jiyangfei

相关资讯

PRS:植入物方案改良,乳房重建的成本更低了!

采用下方脱细胞真皮基质和上部Vicryl网片重建胸前乳房是一种安全的技术,它降低了与支撑材料相关的材料成本,并使外科医生能够精确地控制植入物的囊腔容积和位置。

PRS:人群众包评估乳房重建术后的美学效果快速、可靠又有效

评估乳房再造的美学效果可能很困难。患者、外科医生和普通人群在成功结果的构成方面可能会有所不同。

乳腺癌术后乳房重建中国专家共识(2019版)

乳腺癌是我国女性发病率排名第一的恶性肿瘤[1]。目前,约70%以上的我国乳腺癌病人仍然接受乳房切除手术。乳房缺失给病人带来心理创伤,严重影响女性的生活质量,对具有适应证的乳腺癌病人实施乳房重建已经在国内外获得广泛认同。为推动我国乳腺癌术后乳房重建的规范化进程,中华医学会外科学分会乳腺外科学组在复习文献的基础上,结合中国乳腺癌术后乳房重建的临床现状展开深入讨论,并针对其适应证与禁忌证以及技术操作原则

PRS:乳房重建选什么假体?毛面组织扩张器会影响二期假体乳房重建的结果吗?

组织扩张器的类型可能影响二期植入物乳房重建的效果,微毛面扩张器和粗毛面扩张器的安全性基本可以接受。

JAMA Surg:新辅助化疗后乳腺癌患者保乳手术后乳房重建vs全乳切除对长期预后的影响

对于乳腺癌患者,在新辅助化疗后,保乳手术后乳房重建患者的长期肿瘤学结果与全乳切除相当

JAMA Surg:乳腺癌患者乳房重建移植物类型与复发风险研究

乳腺癌患者在接受全乳切除后,若接受有纹理移植物重建导致乳腺癌复发风险增加

拓展阅读

Blood:20号染色体缺失是乳房植入物相关间变性大细胞淋巴瘤的特征!

乳房植入相关间变性大细胞淋巴瘤(BIA-ALCL)是一种非常罕见的由单一环境刺激引起的T细胞淋巴瘤

Blood:20号染色体丢失是乳房植入物相关间变性大细胞淋巴瘤的特征

染色体20q13.13的频繁丢失为识别BIA-ALCL是一个单独的疾病实体提供了遗传学依据。BIA-ALCL中普遍存在的染色体变异可能是针对与乳房植入物相关的血清肿的女性进行敏感筛查的基础。